tilatamig samrotecan (AZD9592)

News alerts, weekly reports and conference planners

Company:

AstraZeneca

Drug class:

Topoisomerase I inhibitor, EGFR-targeted antibody-drug conjugate, c-MET-targeted antibody-drug conjugate

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	AZD9592 Sensitive: D – Preclinical AZD9592 Sensitive : D	AZD9592 Sensitive: D – Preclinical AZD9592 Sensitive : D
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	osimertinib + AZD9592 Sensitive: D – Preclinical osimertinib + AZD9592 Sensitive : D	osimertinib + AZD9592 Sensitive: D – Preclinical osimertinib + AZD9592 Sensitive : D

Associations
(2)